Literature DB >> 22051531

An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.

C Teodosio1, A C García-Montero, M Jara-Acevedo, I Alvarez-Twose, L Sánchez-Muñoz, J Almeida, J M Morgado, A Matito, L Escribano, A Orfao.   

Abstract

D816V KIT mutation of bone marrow (BM) mast cells (MC) is a common feature to systemic mastocytosis (SM) patients. Nevertheless, occurrence of the KIT mutation in BM cell compartments other than MC is associated with progression to more aggressive forms of the disease and poor outcome in indolent SM (ISM). Here, we assessed the potential association between the immunophenotype of MC and multilineage KIT mutation in the BM of SM patients through the investigation of the flow cytometric protein expression profile (PEP) of bone marrow mast cells (BMMC) from 70 control individuals and 206 SM patients, classified according to the WHO (World Health Organization), and the degree of involvement of BM hematopoiesis by the D816V KIT mutation; additionally, we developed a score-based class prediction algorithm for the detection of SM cases with multilineage mutation. Our results show that aberrant expression of CD25 with a FcɛRI(lo), FSC(lo), SSC(lo) and CD45(lo) immature phenotype of BMMC, in the absence of coexisting normal MC in the BM, was associated with multilineage involvement by the D816V KIT mutation, regardless of the diagnostic subtype of the disease (for example, indolent vs aggressive SM), which supports the utility of the immunophenotype of BMMC as a surrogate marker to screen for multilineage KIT mutation in ISM.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22051531     DOI: 10.1038/leu.2011.293

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  14 in total

1.  Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression.

Authors:  A Mayado; C Teodosio; A C Garcia-Montero; A Matito; A Rodriguez-Caballero; J M Morgado; C Muñiz; M Jara-Acevedo; I Álvarez-Twose; L Sanchez-Muñoz; S Matarraz; C Caldas; J I Muñoz-González; L Escribano; A Orfao
Journal:  Leukemia       Date:  2015-07-08       Impact factor: 11.528

2.  Mutational profiling in the peripheral blood leukocytes of patients with systemic mast cell activation syndrome using next-generation sequencing.

Authors:  Janine Altmüller; Britta Haenisch; Amit Kawalia; Markus Menzen; Markus M Nöthen; Heide Fier; Gerhard J Molderings
Journal:  Immunogenetics       Date:  2017-04-06       Impact factor: 2.846

3.  Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications.

Authors:  Maria Jara-Acevedo; Cristina Teodosio; Laura Sanchez-Muñoz; Ivan Álvarez-Twose; Andrea Mayado; Carolina Caldas; Almudena Matito; José M Morgado; Javier I Muñoz-González; Luis Escribano; Andrés C Garcia-Montero; Alberto Orfao
Journal:  Mod Pathol       Date:  2015-06-12       Impact factor: 7.842

4.  CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.

Authors:  Georg Greiner; Nadine Witzeneder; Angelika Berger; Klaus Schmetterer; Gregor Eisenwort; Ana-Iris Schiefer; Simone Roos; Theresia Popow-Kraupp; Leonhard Müllauer; Johannes Zuber; Veronika Sexl; Lukas Kenner; Wolfgang R Sperr; Peter Valent; Matthias Mayerhofer; Gregor Hoermann
Journal:  Blood       Date:  2016-11-16       Impact factor: 22.113

Review 5.  Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.

Authors:  Peter Valent; Cem Akin; Karin Hartmann; Gunnar Nilsson; Andreas Reiter; Olivier Hermine; Karl Sotlar; Wolfgang R Sperr; Luis Escribano; Tracy I George; Hanneke C Kluin-Nelemans; Celalettin Ustun; Massimo Triggiani; Knut Brockow; Jason Gotlib; Alberto Orfao; Lawrence B Schwartz; Sigurd Broesby-Olsen; Carsten Bindslev-Jensen; Petri T Kovanen; Stephen J Galli; K Frank Austen; Daniel A Arber; Hans-Peter Horny; Michel Arock; Dean D Metcalfe
Journal:  Cancer Res       Date:  2017-03-02       Impact factor: 12.701

6.  New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019.

Authors:  Michel Arock; Karl Sotlar; Jason Gotlib; Wolfgang R Sperr; Karin Hartmann; Lawrence B Schwartz; Cem Akin; Hans-Peter Horny; Peter Valent
Journal:  Leuk Lymphoma       Date:  2019-12-26

Review 7.  KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis.

Authors:  M Arock; K Sotlar; C Akin; S Broesby-Olsen; G Hoermann; L Escribano; T K Kristensen; H C Kluin-Nelemans; O Hermine; P Dubreuil; W R Sperr; K Hartmann; J Gotlib; N C P Cross; T Haferlach; A Garcia-Montero; A Orfao; J Schwaab; M Triggiani; H-P Horny; D D Metcalfe; A Reiter; P Valent
Journal:  Leukemia       Date:  2015-02-04       Impact factor: 11.528

8.  Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive.

Authors:  Magalie Joris; Sophie Georgin-Lavialle; Marie-Olivia Chandesris; Ludovic Lhermitte; Jean-François Claisse; Danielle Canioni; Katia Hanssens; Gandhi Damaj; Olivier Hermine; Mohammed Hamidou
Journal:  Case Rep Hematol       Date:  2012-09-10

9.  Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome.

Authors:  Almudena Matito; José Mario Morgado; Iván Álvarez-Twose; Laura Sánchez-Muñoz; Carlos Eduardo Pedreira; María Jara-Acevedo; Cristina Teodosio; Paula Sánchez-López; Elisa Fernández-Núñez; Ricardo Moreno-Borque; Andrés García-Montero; Alberto Orfao; Luis Escribano
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

10.  De novo leukemic variant of mast cell leukemia with KIT D816V.

Authors:  Hae In Bang; Rojin Park; Eun Su Park; In Ho Choi; Kyoung Ha Kim; Jeong Won Shin; Tae Youn Choi; Kyungja Han; Jong-Ho Won
Journal:  Ann Lab Med       Date:  2015-02-12       Impact factor: 3.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.